Low Risk of Hyperprogression with First-Line Chemoimmunotherapy for Advanced Non-Small Cell Lung Cancer: Pooled Analysis of 7 Clinical Trials

BACKGROUND: Monotherapy immune checkpoint inhibitor (ICI) used in second- or later-line settings has been reported to induce hyperprogression. This study evaluated hyperprogression risk with ICI (atezolizumab) in the first-, second-, or later-line treatment of advanced non–small cell lung cancer (NS...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Lee X, Cappuzzo, Federico, Matos, Ignacio, Socinski, Mark A, Hopkins, Ashley M, Sorich, Michael J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Lung Cancer
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10078909/
https://www.ncbi.nlm.nih.gov/pubmed/36905578
http://dx.doi.org/10.1093/oncolo/oyad043

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10078909/
https://www.ncbi.nlm.nih.gov/pubmed/36905578
http://dx.doi.org/10.1093/oncolo/oyad043

Ejemplares similares